Dynamics of ctDNA may serve as an early predictor of response to nontargeted chemotherapy of advanced lung cancer patients

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F26475821%3A_____%2F20%3AN0000002" target="_blank" >RIV/26475821:_____/20:N0000002 - isvavai.cz</a>

Výsledek na webu

<a href="https://clincancerres.aacrjournals.org/content/26/11_Supplement/A30" target="_blank" >https://clincancerres.aacrjournals.org/content/26/11_Supplement/A30</a>

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Dynamics of ctDNA may serve as an early predictor of response to nontargeted chemotherapy of advanced lung cancer patients

Popis výsledku v původním jazyce

Poster at AACR, Miami, CLINICAL CANCER RESEARCH Meeting Abstract: A30 Volume: 26 Issue: 11 Pages: 50-50 Supplement: S Published: JUN 2020, WOS:000537848000063: Liquid biopsy methodology has long been utilized in management of patients with advanced lung cancer. The approach found its use in testing for a presence of somatic mutations of EGFR gene in circulating tumor DNA (ctDNA) to predict antiEGFR therapy response or resistance. More recently, ctDNA is being used as a biomarker for monitoring of the residual disease and early detection of progression or recurrence. The key factor in this case is in quantitative determination of the circulating mutant levels. In our project we have focused on non-small cell (NSCLC) patients receiving chemotherapy. We have first determined a presence of a nontargetable mutation in tumor tissue. Then we have searched for that specific mutation in plasma samples acquired prior and during the chemotherapy. The purpose of the study was to determine utility of ctDNA for evaluation of the disease course. Our data indicate utility of ctDNA in prediction of therapy outcome in NSCLC patients receiving nontargeted chemotherapy. When independently validated, ctDNA could be used to assess efficiency even during the first chemotherapy cycle.

Název v anglickém jazyce

Dynamics of ctDNA may serve as an early predictor of response to nontargeted chemotherapy of advanced lung cancer patients

Popis výsledku anglicky

Poster at AACR, Miami, CLINICAL CANCER RESEARCH Meeting Abstract: A30 Volume: 26 Issue: 11 Pages: 50-50 Supplement: S Published: JUN 2020, WOS:000537848000063: Liquid biopsy methodology has long been utilized in management of patients with advanced lung cancer. The approach found its use in testing for a presence of somatic mutations of EGFR gene in circulating tumor DNA (ctDNA) to predict antiEGFR therapy response or resistance. More recently, ctDNA is being used as a biomarker for monitoring of the residual disease and early detection of progression or recurrence. The key factor in this case is in quantitative determination of the circulating mutant levels. In our project we have focused on non-small cell (NSCLC) patients receiving chemotherapy. We have first determined a presence of a nontargetable mutation in tumor tissue. Then we have searched for that specific mutation in plasma samples acquired prior and during the chemotherapy. The purpose of the study was to determine utility of ctDNA for evaluation of the disease course. Our data indicate utility of ctDNA in prediction of therapy outcome in NSCLC patients receiving nontargeted chemotherapy. When independently validated, ctDNA could be used to assess efficiency even during the first chemotherapy cycle.

Druh

O - Ostatní výsledky

CEP obor

—

OECD FORD obor

30204 - Oncology

Projekt

<a href="/cs/project/NV17-30748A" target="_blank" >NV17-30748A: Nová metoda kombinace funkčních zobrazovacích metod a nádorové genomiky pro neinvazivní fenotypizaci a sledování efektu léčby plicních karcinomů</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2020

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů